Statement of Need

The need for these activities has been determined based on identifying professional practice gaps, as well as review of previous course evaluations and member surveys. The educational content was developed based on current issues and topic trends provided by the Southern Sleep Society leadership and membership.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American Academy of Sleep Medicine and The Southern Sleep Society. The American Academy of Sleep Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure Statement

As an education provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Academy of Sleep Medicine must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All product developers, planners, and speakers are expected to disclose any relevant financial interest or other relationships held by the individual, or members of their family, that are relevant to the presentation over the preceding twelve months with (1) manufacturers of any commercial products and/or providers of commercial services, (2) any commercial supporters, (3) any off-label or investigational uses of products. The individual is also required to disclose if he/she has no relationships with any manufacturers, products or services that are relevant to the presentation. The ACCME Standards for Commercial Support require accredited CME providers to resolve all identified potential conflicts of interest with any individual in a position to influence and/or control the content of CME activities prior to the education activity being delivered to learners.

Resolution of Conflicts of Interest

AASM has implemented mechanisms to identify and mitigate conflicts of interest for all individuals in a position to control content, prior to the planning and implementation of these CME activities. **Course Chair(s) review the COI declarations to satisfy no commercial bias exists.** All Conflict of Interest Disclosures are provided to participants prior to start of the activity.

Faculty Disclosures:

The following Southern Sleep Society faculty members have no relevant relationships with any commercial interests to disclose:

Timothy Morgenthaler, MD, Byron Jamerson, RPSGT, CCSH, Kristina Weaver, EMT-P, RPSGT, Laura Linley, RPSGT, RST, CRT, Patrick Sorenson, RPSGT, Joel Porquez, RPSGT, RST, Patrick Sorenson, RPSGT, Debbie Akers, RRT, RPSGT, Marilyn Swick, RPSGT, Timothy Morgenthaler, MD, Peter C. Gay, MD, Nilgun Giray, MD, PhD, Carlos Scheck, MD, Amir Sharafkhaneh, MD, Romy Hoque, MD, Mary Rose, PsyD, DBSM, CBSM, Michael Nadorff, PhD, Shariar Shahzeidi, MD, Ruckshanda Majid, Md. Kathy Richards, PhD, RN, FAAN, Gregory Carter, MD, PhD, Dave Balachandran, MD, Lilit Sargsyan, MD, Ashley Knox, MS, APRN, FNP-C, Tamara De Lumban, APRN.

The following faculty members disclosed the following:

Tammy Muth-Davis, BS, RPSGT, RRT disclosed:

Donald Bliwise, PhD disclosed:
Consultant: Merck, Ferring, Eisai, Huxley.

Updated 3.26.2021
Citations:

David Rye, MD disclosed:
Grant/Research Support: Research Support: ACTIVE NS113912 Rye (Co-I) – 7.5% effort (09-01-2019-8/31/2024) Mechanisms and regulation of brain iron uptake Project Narrative: This study employs cell and animal models and human biospecimens (e.g., cerebrospinal fluids) to investigate the molecular mechanisms governing iron transport across the blood-brain-barrier (i.e., into and out of the brain). NS111280 Rye (Co-I) – 5% effort (08/01/2019 – 7/31/2024) Antibiotic-mediated improvements in vigilance: mechanisms of action of clarithromycin in hypersomnia syndromes Project Narrative: This study investigates the mechanisms inclusive of brain circuits underlying clinical relevant hypersomnia/somnolence refractory to traditional wake promoting drugs such as psychostimulants, but, responsive to the macrolide antibiotic clarithromycin.

Investigational Device/Drug: Dr. Rye is a co-inventor on United States Patent Application 20110028418 that describes the use of GABA-A receptor antagonists for the treatment of excessive sleepiness and sleep disorders associated with excessive sleepiness. Direct Link: http://emoryott.technologypublisher.com/technology/2291. This has provided rationale for two registered, multi-center clinical trials now completed (ARISE-1 and ARISE-2) for the treatment of idiopathic hypersomnia.

Consultant: Jazz Pharmaceuticals, Takeda Pharmaceuticals, Harmony Biosciences, Eisai Pharmaceuticals, Major League Baseball, Garland, Samuel, & Loeb, P.C.

Stock/Stockholder: Family: Sage Therapeutics, Roche Holdings

Royalties: Dr. Rye has received royalties per a licensing agreement between Emory University and Balance Therapeutics describing the use of GABA-A receptor antagonists for the treatment of excessive sleepiness and sleep disorders associated with excessive sleepiness. Dr. Rye has also received royalties per a licensing agreement between Emory University and Expansion therapeutics describing use of GABA-A receptor antagonists for the treatment of excessive sleepiness and associated (cognitive) disorders in myotonic dystrophy.


Citations:

Arthur Walters, MD disclosed:
Grant/Research Support: (1) Xenoport/Arbor grant support for study to determine the pharmacokinetic properties and therapeutic efficacy of gabapentin enacarbil in Restless Legs Syndrome (2)NIH ROI grant to determine the role of body metals in Restless Legs Syndrome. (3) Grant from MundiPharma to construct an opiate receptor knock out mouse model of Restless Legs Syndrome.

Consultant: (1) Member of the Medical Advisory Board of the Restless Legs Syndrome Foundation (RLSF). (2) Member of the Executive Committee of the International Restless Legs Syndrome Study Group (IRLSSG).

Citations:

Updated 3.26.2021

Margaret Hovda, MD disclosed:
Speakers' bureau: Inspire Medical Systems.

Citations:

Lynn Marie Trotti, MD disclosed:
Other financial/material support: Funds to my institution (none to me) for the pitolisant EAP.
Investigational Device/Drug: IND for flumazenil for hypersonnia.

Citations:

Asim Roy, MD disclosed:
Grant/Research Support: Jazz, Inspire, Eisai, Avadel, Suven, Takeda, Harmony, Nyxoah
Speakers' bureau: Jazz Pharma, Eisai, Inspire, Harmony Bioscience, Vanda

Citation:
Patrick J. Strollo, Jr., M.D., ""Upper-Airway Stimulation for Obstructive Sleep Apnea"". N Engl J Med 2014; 370:139-149

Planner Disclosures:
The Southern Sleep Society planners have no relevant relationships with any commercial interests to disclose:

Marietta Bibbs, RPSGT (Chair)
Mary Rose, PsyD
Denise Sharon, MD, PhD